Portola Pharma (PTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 116,640 | 40,130 | 22,546 | 35,504 | 12,070 |
| Cost of Goods | 44,378 | 18,081 | 415 | N/A | N/A |
| Gross Profit | 72,262 | 22,049 | 22,131 | 35,504 | 12,070 |
| Operating Expenses | 343,924 | 367,450 | 295,225 | 305,089 | 239,245 |
| Operating Income | -271,284 | -345,320 | -272,679 | -269,585 | -227,175 |
| Interest Expense | 31,290 | 18,740 | 11,603 | 61 | 0 |
| Other Income | 9,698 | 13,516 | -1,338 | 1,533 | 305 |
| Pre-tax Income | -292,876 | -350,544 | -285,620 | -268,113 | -226,870 |
| Income Tax | N/A | N/A | N/A | N/A | -365 |
| Net Income Continuous | -292,876 | -350,544 | -285,620 | -268,113 | -226,505 |
| Minority Interests | -2,213 | -321 | 470 | 930 | N/A |
| Net Income | $-290,663 | $-350,223 | $-286,090 | $-269,043 | $-226,505 |
| EPS Basic Total Ops | -4.06 | -5.31 | -4.81 | -4.76 | -4.36 |
| EPS Basic Continuous Ops | -4.09 | -5.31 | -4.80 | -4.75 | -4.36 |
| EPS Diluted Total Ops | -4.06 | -5.31 | -4.81 | -4.76 | -4.36 |
| EPS Diluted Continuous Ops | -4.09 | -5.31 | -4.80 | -4.75 | -4.36 |
| EPS Diluted Before Non-Recurring Items | -4.06 | -5.01 | -4.81 | -4.76 | -4.36 |
| EBITDA(a) | $-266,358 | $-344,082 | $-270,504 | $-266,548 | $-222,690 |